185 results match your criteria: "Urological Research Institute (URI).[Affiliation]"
BJU Int
January 2025
Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cancers (Basel)
December 2024
Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy.
: PSMA PET radiomics is a promising tool for primary prostate cancer (PCa) characterisation. However, small single-centre studies and lack of external validation hinder definitive conclusions on the potential of PSMA PET radiomics in the initial workup of PCa. We aimed to validate a radiomics signature in a larger internal cohort and in an external cohort from a separate centre.
View Article and Find Full Text PDFFront Pharmacol
November 2024
Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eur Urol Oncol
September 2024
The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Minerva Urol Nephrol
October 2024
Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eur Urol Oncol
September 2024
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy; European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, The Netherlands. Electronic address:
Chin Clin Oncol
August 2024
ORSI Academy, Melle, Belgium; Department of Urology, OLV, Aalst, Belgium.
Proc Natl Acad Sci U S A
September 2024
Division of Experimental Oncology, Urological Research Institute (URI), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan 20132, Italy.
Residual nonvisible bladder cancer after proper treatment caused by technological and therapeutic limitations is responsible for tumor relapse and progression. This study aimed to demonstrate the feasibility of a solution for simultaneous detection and treatment of bladder cancer lesions smaller than one millimeter. The α5β1 integrin was identified as a specific marker in 81% of human high-grade nonmuscle invasive bladder cancers and used as a target for the delivery of targeted gold nanorods (GNRs).
View Article and Find Full Text PDFAsian J Urol
October 2023
Kulkarni Reconstructive Urology Center, 3, Rajpath Society, Paud Road, Pune 411038, India.
Objective: Incidences of post-transurethral resection of the prostate (post-TURP) strictures are between 2.2% and 9.8%.
View Article and Find Full Text PDFKidney Blood Press Res
September 2024
Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA.
Background: Cancer patients are prone to developing acute kidney disease (AKD), yet this phenomenon remains understudied compared to acute kidney injury (AKI). AKD, which often develops insidiously, can cause treatment interruptions, extended hospital stays, and increased mortality.
Summary: This perspective article explores the intricate relationship between AKD and cancer, focusing on prevalence, risk factors, implications for anticancer therapy, and long-term outcomes, including chronic kidney disease progression.
Infertility is a prevalent issue affecting many couples during their reproductive years, with a significant number facing challenges in conceiving despite regular unprotected intercourse. Male factor infertility (MFI) contributes significantly to these cases, with a significant proportion of men lacking an identifiable etiology. As such, a thorough assessment of MFI has become increasingly vital for personalized management.
View Article and Find Full Text PDFBJU Int
December 2024
Kulkarni UroSurgery Institute, Pune, Maharashtra, India.
Eur J Nucl Med Mol Imaging
October 2024
Division of Oncology/Unit of Urology, Gianfranco Soldera Prostate Cancer Lab, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Introduction: Prostate-specific membrane antigen radioguided surgery (PSMA-RGS) might identify lymph node invasion (LNI) in prostate cancer (PCa) patients undergoing extended pelvic lymph node dissection (ePLND). The optimal target-to-background (TtB) ratio to define RGS positivity is still unknown.
Materials & Methods: Ad interim analyses which focused on 30 patients with available pathological information were conducted.
Curr Opin Urol
July 2024
IRCCS San Raffaele Scientific Institute, Urological Research Institute (URI).
Minerva Urol Nephrol
April 2024
Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Minerva Urol Nephrol
April 2024
Division of Experimental Oncology, Department of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Kidney Blood Press Res
June 2024
Department of Nephrology, Dialysis, and Transplantation, ARNAS G. Brotzu, Cagliari, Italy.
Background: In the era of precision medicine, determining reliable renal function assessment remains a critical and debatable issue, especially in nephrology and oncology.
Summary: This paper delves into the significance of accurately measured glomerular filtration rate (mGFR) in clinical practice, highlighting its essential role in guiding medical decisions and managing kidney health, particularly in the context of renal cancer (RC) patients undergoing nephrotoxic anti-cancer drugs. The limitations and advantages of traditional glomerular filtration rate (GFR) estimation methods, primarily using serum biomarkers like creatinine and cystatin C, are discussed, emphasizing their possible inadequacy in cancer patients.
Minerva Urol Nephrol
February 2024
Unit of Urology, Department of Oncology, G. Martino Polyclinic Hospital, Messina, Italy.
Cancers (Basel)
January 2024
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC H2X 3E4, Canada.
Background: It is unknown whether more complex UD, such as orthotopic neobladder and abdominal pouch, may be associated with higher OCM rates than ileal conduit. We addressed this knowledge gap within the SEER database 2004-2020.
Methods: All T1-T4aNM radical cystectomy (RC) patients were identified.
Urol Oncol
February 2024
Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, Québec, Canada.
Minerva Pediatr (Torino)
October 2023
Division of Urology, Ng Teng Fong General Hospital, National University Health System, Singapore, Singapore.
Background: The aim of this study was to evaluate thulium fiber laser (TFL) safety and efficacy compared to high-power (HP) Holmium:YAG laser in pediatric patients who have undergone retrograde intrarenal surgery (RIRS) for kidney stones.
Methods: We retrospectively reviewed data from pediatric patients who underwent RIRS for kidney stones between 2018 and 2020. Complications were assessed 4-6 weeks postoperatively.
Int Urol Nephrol
March 2024
Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.
Purpose: Aim of the present study was to develop and validate a nomogram to accurately predict the risk of chronic kidney disease (CKD) upstaging at 3 years in patients undergoing robot-assisted partial nephrectomy (RAPN).
Methods: A multi-institutional database was queried to identify patients treated with RAPN for localized renal tumor (cT1-cT2, cN0, cM0). Significant CKD upstaging (sCKD-upstaging) was defined as development of newly onset CKD stage 3a, 3b, and 4/5.
Cancers (Basel)
September 2023
Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy.
Localized prostate cancer (PCa) can be treated with radical prostatectomy (RP). Up to 30% of patients undergoing this procedure experience biochemical recurrence (BCR), namely the rise in serum prostate-specific antigen (PSA) levels during the post-surgical follow-up, requiring further treatments and with the risk of severe disease progression. Currently, the most accurate imaging technique to confirm, detect, and locate disease relapses in BCR patients is prostate-specific membrane antigen (PSMA)-targeted PET, as recommended by international clinical guidelines.
View Article and Find Full Text PDFMinerva Urol Nephrol
October 2023
Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.